Abstract
Introduction: One of the biggest health challenges in the world is to reduce cardiovascular complications in patients with chronic kidney disease. Recent evidence has shown that gliflozins are associated with a reduced risk of death from cardiovascular causes in diabetic individuals. The potential extent of this benefit to dialysis patients is limited by the lack of safety studies for thi…